2018 Pipeline Review for Anaplastic Oligoastrocytoma: H1 Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively.

Companies Mentioned

  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Pfizer Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Anaplastic Oligoastrocytoma - Overview
  4. Anaplastic Oligoastrocytoma - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Anaplastic Oligoastrocytoma - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development
  14. Anaplastic Oligoastrocytoma - Drug Profiles

For more information about this report visit https://www.researchandmarkets.com/research/8q8w8c/2018_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs